Navigation Links
Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas
Date:12/14/2009

y due to busy schedules, social gatherings, and the pain associated with over activity. However, for many women living with RA this isolation and pain is a common feeling," said Dr. Vibeke Strand, Adjunct Clinical Professor, Division of Immunology/Rheumatology of Stanford University School of Medicine. "More often, many prefer to hide their degree of pain and discomfort from family and friends to avoid hindering the festive celebrations which can lead to a feeling of isolation."

Daily pain is an issue - 63% of respondents live with pain - this can be exacerbated by the dexterity needed for even the simplest of Christmas tasks which is illuminated by the survey with 28% of moderate to severe RA respondents always experiencing pain, find it more difficult or have stopped writing cards altogether.

Shopping for gifts, preparing food, writing cards and wrapping presents are the four festive activities that women living with RA find most difficult to do. Among these women, 28% experience pain and difficulty when shopping for gifts, or have stopped altogether, and more than a quarter report it painful to prepare festive food.

"Nearly two thirds of women living with RA experience pain every day which can be more intense during busy times of the year, such as Christmas and this can seriously impact a patient's enjoyment of the festive season. Almost half of patients included in the survey are not talking to their physician about pain control options which is imperative to enable them to take control of their pain, especially around Christmas when pain can be a considerable issue. This will ensure that more patients achieve a pain free 'good day' and ultimately improve their quality of life." Said Professor Paul Emery, Professor of Rheumatology, University of Leeds.

In light of these survey findings UCB has developed the "12 Tips of Christmas" with tips on how to manage and enjoy the hectic holiday sea
'/>"/>

SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis
2. New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
3. UCBs Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis
4. New Survey Shows Devastating Impact of Rheumatoid Arthritis Pain on Intimate Relations
5. Video: New Way RA(TM) Talk Show Premieres Online for People Living With Rheumatoid Arthritis (RA)
6. New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives
7. Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
8. Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models
9. Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis
10. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
11. Use of Biologic Agents Continues to Expand Among US Rheumatologists - Can New Agents Shift the Treatment Paradigm in Rheumatoid Arthritis?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Sales Horizons, a leader in sales ... training programs for companies engaged in complex B2B sales. ... thousands of salespeople over 25 years in market-leading Fortune ... be customized to address the unique sales challenges of ... training program consists of two parts: Mastering the ...
(Date:7/30/2014)... 30, 2014 BCC Research ( http://www.bccresearch.com ... for Enzymes in Industrial Applications , the global market ... $7.1 billion by 2018, registering a five-year compound annual ... to be recorded in the detergent enzyme segment with ... Enzyme technology has influenced almost every sector of industrial ...
(Date:7/30/2014)... July 30, 2014  Dyadic International, Inc. ("Dyadic") ... patented and proprietary technologies are used to discover, ... for the bioenergy, bio-based chemical, biopharmaceutical and industrial ... "Tom" Dubinski as Vice President and Chief Financial ... financial and information technology operations for Dyadic and ...
(Date:7/30/2014)... MARLBOROUGH, Mass. , July 30, 2014 ... RXII ), a biotechnology company focused on ... major unmet medical needs using RNA-targeted technologies, ... study (RXI-109-1402) with RXI-109, for the reduction ... scar revision surgery, has been initiated. ...
Breaking Biology Technology:Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5
... FRANCISCO, Calif., Jan. 4 Cerimon,Pharmaceuticals, Inc. announced ... Counsel, a newly established position, and Vice President ... global life sciences,executive and corporate attorney with broad ... in the US and,Europe. In the business development ...
... efficacy in treatment of multi-drug ... resistant infections -, ... "Company"), a biopharmaceutical company focused on the,development of novel antibiotics for ... patients in two,separate Phase 2 clinical trials. The studies will evaluate ...
... and biotechnology ... expertise, BOSTON, Jan. 3 Observant LLC has ... for research excellence,and a commitment to client service. John ... firm as Vice President. Dr. Hartman,s,research has focused on ...
Cached Biology Technology:Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing 2Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 2Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 3Observant LLC Expands Senior Management Team 2
(Date:7/30/2014)... July 30, 2014 NexID Biometrics ... liveness detection solutions for the biometric authentication industry, ... consortium revolutionizing online authentication with standards for strong ... , "The decision to join FIDO Alliance stems ... pervasive in use. We believe the FIDO Alliance ...
(Date:7/30/2014)... Scientists are searching through a massive collection of 20-million-year-old ... years ago, and the effort is yielding fresh insights ... , When the collection is fully curated, a task ... largest unbiased Dominican amber collection in the world, the ... thus far is that of a pygmy locust, a ...
(Date:7/30/2014)... in cancer treatment has been shown to relieve ... for neural transmission between the peripheral and central ... Institute of Radiation Medicine, Chinese Academy of Medical ... into rat dorsal root ganglia (DRG) to provide ... radioactivity (0, 14.8, 29.6 MBq) were implanted separately ...
Breaking Biology News(10 mins):NexID Biometrics Joins the FIDO Alliance 2Decades-old amber collection offers new views of a lost world 2
... 21 February 2011 Elsevier, a world-leading publisher ... services, and TAIR - The Arabidopsis Information Resource, ... elements of scientific research. All articles on Elsevier,s ... genes and use AGI codes (e.g. AT4G32520) will ...
... Researchers at Albert Einstein College of Medicine ... to protect against an increasingly common and particularly deadly form ... tested in an animal model, are reported in a paper ... Pneumococcal pneumonia can occur when the lungs are ...
... heart diseases affect approximately one in 100 patients, making ... number-one cause of pediatric deaths. Now a new ... cardiac muscle damage in a mouse model of the congenital ... treatment for this rare condition, but also demonstrates the importance ...
Cached Biology News:Vaccine made with synthetic gene protects against deadly pneumonia 2Vaccine made with synthetic gene protects against deadly pneumonia 3Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndrome 2Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndrome 3
... Gene Expression (SAGE) is a powerful ... a cost-effective outsourcing solution for sequencing ... Agencourt's SAGE sequencing service provides our ... long Phred20 read lengths (40 SAGE ...
... Sciences can provide custom microplate coating using advanced automated high ... of plate formats. We can also accommodate virtually any lot ... 0.5-320 L):, , 8 ... well microplate, 384 well microplate, ...
... ) The antibody is preadsorbed to remove any ... buffered aqueous glycerol solution A solution ... 2+ and Ca 2+ ), pH 7.3 ... (IgG, protease free) and 0.05% sodium azide A ...
... Cytometry The Guava EasyCyte system is ... multiparameter cytometer with built-in 96-well microplate sampling ... plates of cells and compounds quickly and ... tubes or having the carryover issues found ...
Biology Products: